Long-term results in patients treated with thrombolysis, thoracic inlet decompression, and subclavian vein stenting for Paget-Schroetter syndrome  by Kreienberg, Paul B. et al.
S100
More recent therapeutic approaches have demonstrated
that lytic therapy is effective in reestablishing patency of the
thrombosed subclavian vein.5-8 However, thrombolysis does
not obviate the need for thoracic inlet decompression, which
produces better long-term results in these patients.6,7 Some
investigators advocate a staged approach that delays thoracic
inlet decompression for 3 to 4 months.6,7 In spite of the
decompressed thoracic inlet, a high incidence of persistent
stenosis in the subclavian vein is a common finding.5,8 The
chronically injured segment of vein is prone to repeat throm-
bosis before surgical decompression during the 3-month
period of anticoagulation. As many as 10% of the patients
who are treated in this manner will sustain a recurrent
thrombosis.7 This treatment protocol only delays the defini-
tive treatment of Paget-Schroetter syndrome.
This study reviews our experience with a treatment pro-
tocol that uses thrombolysis followed by immediate thoracic
inlet decompression and percutaneous transluminal angio-
plasty (PTA) and/or intraluminal stenting of residual subcla-
vian vein stenoses.
PATIENTS AND METHODS
Between 1994 and 2000, 23 consecutive patients were
treated at the Vascular Institute at the Albany Medical
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Purpose: In an effort to minimize long-term disability related to effort thrombosis of the subclavian vein, selected
patients were treated with thrombolysis, thoracic inlet decompression, percutaneous transluminal angioplasty (PTA),
and subclavian vein stenting. We evaluated the long-term outcomes of patients treated with this algorithm. 
Methods: Between 1994 and 2000, 23 patients were evaluated with effort thrombosis of the subclavian vein.
Thrombolysis was instituted on an average of 9.4 days (range, 1-30 days) after initial onset of symptoms. Average time
to clot lysis was 34 hours (range, 12-72 hours). After immediate supraclavicular thoracic inlet decompression, all
patients underwent PTA. Fourteen patients with residual vein stenosis (>50%) after PTA underwent stenting of the
subclavian vein. Complications in this series included three wound hematomas that required drainage in two patients
and one subpleural hematoma that required thoracotomy for decompression.
Results: All patients who underwent PTA are patent, with a mean follow-up of 4 years (range, 2-6 years). In the veins
treated with stents, 9 of 14 veins are patent, with a mean follow-up of 3.5 years (range, 1-6 years). Two veins had early
occlusions (2 days); two veins occluded at 1 year; and seven veins occluded at 3 years. Three of the patients (including
those patients who experienced the early failed procedures) were later identified with factor V Leiden. Early failures
also had clot extending into the brachial vein.
Conclusion: Patients with short-segment venous strictures after successful lysis and thoracic outlet decompression may
safely be treated with subclavian venous stents and can expect long-term patency. (J Vasc Surg 2001;33:S100-5.)
Primary subclavian vein thrombosis (effort thrombosis)
is an entity that typically affects young, healthy, active peo-
ple. Delineation of the appropriate treatment algorithm has
been in evolution since this syndrome was first described.1
Conservative treatment includes resting the extremity, eleva-
tion, and anticoagulation, which results in significant long-
term disability. As many as 75% of patients have residual
symptoms at follow-up.2 To improve functional outcome,
numerous approaches to this problem have been proposed,
including a staged approach that uses anticoagulation then
thoracic inlet decompression, venous thrombectomy with
first rib resection, and venous bypass procedures.1-5
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Center Hospital for a diagnosis of Paget-Schroetter syn-
drome. Diagnosis was made on clinical evaluation and con-
firmed with venography. After venography and identification
of subclavian thrombus, thrombolytic therapy was instituted
in all cases. The thrombus was traversed with a guidewire
and a multi-sidehole Mewissen catheter (Meditech, Natick,
Mass) was placed within the thrombus for delivery of the
thrombolytic agent. Most of the patients (20/24 patients)
received urokinase therapy. Patients who received urokinase
therapy were given a lacing bolus of 200,000 U. Infusion
was then maintained at a variable rate between 150,000 and
250,000 U/hr for 6 hours and then between 60,000 and
100,000 U/hr. In patients who received tissue plasminogen
activator, the initial therapy began at 4 mg/hr for 6 hours
and decreased to 1 to 2 mg/hr. Patients were reevaluated
with venography at 6 hours and every 12 hours thereafter.
Thrombolytic therapy continued until thrombus dissolution
was achieved or until there was no progression of thrombol-
ysis on sequential examinations. Heparin was administered
concomitantly as a 5000-U intravenous bolus, and then a
continuous infusion of 800 U/hr was administered. The
partial thromboplastin time (pTT) ratio was monitored, and
the infusion rate was adjusted to maintain the pTT ratio at
2.0 to 2.5 times normal. All patients were monitored in the
surgical intensive care unit while undergoing thrombolytic
therapy.
After successful thrombolysis, patients were main-
tained on intravenous heparin and taken to the operating
room within 24 hours of the final venogram. Surgical
intervention was approached as an exploration to assess
the anatomy of the thoracic inlet. All procedures were per-
formed through a supraclavicular approach because this
allows access to perform a complete venolysis in these
patients. The anterior scalene muscle was removed in its
entirety from the insertion on the first rib to the origin of
the transverse cervical processes. The rib was removed
anteriorly, including approximately 1 cm of the costal car-
tilage, and extended laterally as much as 3 to 4 cm in
length. Patients underwent venolysis. Adequate space was
created for the vein in the relaxed and stressed position.
All wounds were drained at the completion of the surgical
procedure.
All but one patient went directly from the operating
room to the vascular radiology suite for venography and
PTA and/or stenting of the subclavian vein; the remaining
patient went the morning after the procedure. All patients
underwent PTA. In patients in whom stents were placed,
at least a 50% residual stenosis remained in the vein in the
unstressed position after PTA alone. The length of the
stents placed was determined by adding approximately 2
cm to the apparent length of the lesion.
Patients were maintained on intravenous heparin
(pTT ratio, 2-2.5) and converted to oral warfarin
(Coumadin; prothrombin time, international normalized
ratio, 2-2.5) before discharge. Coumadin anticoagulation
continued between 6 and 18 months, except for those
patients who were identified later to have hypercoagulable
states. Hypercoagulable studies were not routinely sent in
this group of patients. Follow-up was performed every 6
months for the first year and then yearly. Subclavian vein
patency was verified by clinical examination and Duplex
ultrasonography at each office visit.
Fig 1. A 36-year-old man with left arm swelling. Subclavian venogram after 12 hours of thrombolytic treatment. Significant stenosis is
present in the patent subclavian vein.
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Additional data were obtained by a telephone survey.
Patients were contacted, and data were obtained about
changes in occupational or recreational activities, overall
improvement in arm use, and any problems with the other
arm. All patients were sent a letter before the survey and
had the option to decline to participate. All but one
patient participated in the survey. This part of the study
was approved by the Internal Review Board of the Albany
Medical College.
RESULTS
A total of 23 patients were treated with the use of the
algorithm as outlined (12 women and 11 men; average
age, 30.3 years; range, 18-58 years). All patients were
right-hand dominant; 12 patients had left-sided symp-
toms, and 11 patients had right-sided symptoms. Six
patients were initially diagnosed at another hospital
(where intravenous heparin was administered) and then
referred for further therapy. One patient had a stent that
had been placed in the subclavian vein 1 month earlier and
had experienced rethrombosis. Three patients (13%) had a
history of deep venous thrombosis. Seven patients (30%)
had thrombosis associated with exertion or trauma. The
remainder had no associated event. All patients had dis-
comfort and edema in the involved extremity that grew
worse with exertion.
The diagnosis was confirmed by venogram in all cases.
The average time from the start of symptoms to the initi-
ation of thrombolysis was 9.4 days (range, 1-30 days).
Complete thrombosis of the subclavian vein was present in
all cases. All patients underwent thrombolysis after initial
venographic diagnosis (Fig 1). In addition to the subcla-
vian vein, the axillary vein was thrombosed in five patients
(22%) and in the brachial vein in three patients (13%).
Thrombolysis was successful in the dissolution of all
thrombus, except in two cases in which only partial
thrombolysis was achieved. The average time for comple-
tion of lytic therapy was 34 hours (range, 6-72 hours).
After successful thrombolysis, all patients were taken to
the operating room for thoracic outlet decompression,
except two patients who went the next day. All patients
had anterior scalenectomy; 16 patients had first rib resec-
tion. In two patients, clavicular exostoses were also
removed.
Venography after thoracic inlet decompression revealed
persistent stenosis of the subclavian vein in all cases. All
patients underwent PTA of these stenoses; nine patients
had a good result (defined as <50% residual stenosis pre-
sent; Fig 2). Stents were placed in the remaining 14
patients: one 12-mm WallStent (Boston Scientific Vascular,
Natick, Mass), twelve 10-mm WallStents, and one 10-mm
SMART stent (Cordis, Warren, NJ; Fig 3). After stent
placement, patency and the absence of collateral flow were
present in all cases (Fig 4). The overall length of stay for
these patients was 8.3 days (range, 3-43 days).
Complications in this series of patients included three
wound hematomas (two of which required drainage), two
patients with transient brachial plexopathy, and one
patient who experienced the development of a thoracic
hematoma that required decortication in association with
the inadvertent excessive administration of heparin after
operation.
All patients who were successfully treated with PTA
remain asymptomatic in follow-up, without symptoms of
Fig 2. The same patient (in Fig 1) after PTA of residual stenosis (10-mm balloon inflated to 10 atm). Note persistent stenosis.
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swelling or pain. Duplex examination reveals all subclavian
veins in these patients to be patent. The mean patency in
follow-up for these patients is now 4 years (range, 2-6 years;
Table I [online]). In the group of patients who were treated
with stents, eight patients are asymptomatic, and six patients
have complaints of mild swelling. Two patients had early
occlusions within days of stent placement; two patients had
occlusions at 1 year, and another patient had occlusion at 3
years. No evidence of stent fracture was seen in this series
based on the Duplex examination. The mean patency for
the stented subclavian veins is 3 years (range, 2 days–6 years;
Table II [online]). Three of the patients whose veins are
now occluded, including the two patients with early occlu-
sion, have subsequently been identified to have factor V
Leiden, which produces a hypercoagulable state.
Additionally, all early failed procedures were in patients who
had clot in the brachial, axillary, and subclavian vein. One
patient whose procedure was a late failure went on to have
a jugular-venous turndown and is currently symptom free.
All other failed procedures have been accompanied with
complaints of mild limb swelling with activity.
The follow-up telephone survey demonstrated that no
patient has experienced the development of symptoms in
the contralateral limb. All patients in the PTA group con-
tinue the same recreational and occupational activities that
they participated in before the procedure. Three of the 14
patients in the stented group have made changes in their
recreational activities. In two of the three patients, this was
mainly due to continued Coumadin therapy for their
hypercoagulable states (Fig 5). The average reported
recovery time to return to activities was 4.2 weeks (range,
2-12 weeks) in the PTA group and 7 weeks (range, 1-24
weeks) in the stent group.
DISCUSSION
The treatment of Paget-Schroetter syndrome continues
to evolve. Historical approaches that involve only heparin
administration followed by Coumadin anticoagulation clearly
result in significant disability in most active patients.9,10
Currently, the use of thrombolytic therapy for initial
dissolution of the clot has gained acceptance.7,11-15
Catheter-directed administration of thrombolytic agents
can restore patency (within 1 week) in virtually every case
of acute subclavian vein thrombosis.14,15 In the current
series, all but two patients experienced successful complete
dissolution of thrombus. These two patients were evalu-
ated at 10 and 21 days from the onset of symptoms and
required 72 and 48 hours of thrombolysis, respectively.
Venography also revealed an extension of the thrombus
into the brachial, axillary, and subclavian vein.
Treatment after thrombolysis has been studied exten-
sively in the series of articles by Kunkel and Machleder4 and
Machleder.7,16,17 They recommend thoracic outlet decom-
pression in those patients with persistent subclavian vein
stenosis or compression with the arm in the stress position.
This decompression is delayed for 3 months after the initial
thrombolysis. The reasoning is based on the return of the
vein’s thrombolytic properties over time.18 Additionally,
Machleder, himself, has decreased the interval between lysis
and decompression to 4 weeks in selected cases.17 The advan-
tages to a more expedient approach are a quicker return to
normal activity by the patient, a shortened interval that
requires Coumadin anticoagulation, a minimized risk of
recurrent thrombosis and the need for another interval of
thrombolytic therapy, and a potential limit in the development
of large, competitive collateral vessels that may effect subcla-
vian vein patency after treatment.5
Fig 3. Placement of a 12 × 40 mm WallStent for residual stenosis after PTA.
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Beyond thrombolysis and the need for thoracic inlet
decompression is the decision on how to manage the
residual stenosis within the chronically scarred vein lumen.
Several methods for correcting intrinsic stenosis have been
suggested, including venolysis, patch PTA, bypass of the
stenotic segment, and PTA with or without stent place-
ment.19 Our preference is for a catheter-based approach to
manage intrinsic venous lesions after thoracic outlet
decompression. Many would agree that, although PTA
alone before surgical decompression has been condemned,
the best long-term results seem to be after complete tho-
racic inlet decompression and venolysis.7,20 However, the
treatment of significant stenosis after PTA remains an
issue.21 Residual lesions usually represent elastic fibrous
scar within the subclavian vein, which result from chronic
impingement of the vein between the clavicle and the first
rib. Thus, complete treatment for these lesions requires
extrinsic decompression of the vein and treatment of the
intrinsic, chronic vein lesion. If the residual stenosis is due
to the elastic nature of these lesions, then an expandable
stent would offer a reasonable solution.22,23 Early
attempts at their use were associated with stent fracture,
Fig 4. Completion venogram after PTA and venous stent placement.
Fig 5. Results of telephone survey conducted with patients in this study.
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because they were placed without concomitant first rib
resection.24 In fact, one patient who was treated in this
series had undergone the placement of a stent without rib
resection at an outside institution and came to us with a
fractured stent and with the subclavian vein rethrom-
bosed. Our patency data are similar to that of Meier et
al,24 who had seven patent stents between 1 and 3 years of
follow-up. However, they also observed three patients
who experienced occlusion and two incidences of stent
fracture. 
Of interest, on a review of the five patients who later
experienced occlusion, three patients were identified to
have factor V Leiden, which produces a hypercoagulable
state. The two patients in whom the procedure failed at
less than 3 days experienced extensive thrombosis and
longer areas of residual stenosis and therefore required a
longer length of vein to be stented. One of these patients
actually had two stents placed to bridge the affected area.
These factors, in addition to a hypercoagulable state,
appear to be a poor prognostic indicator.
Currently, patients with effort thrombosis of the sub-
clavian vein undergo thrombolysis and then thoracic inlet
decompression for those patients with short-segment sub-
clavian vein stenoses. If intrinsic vein lesions are present
after this, we recommend PTA after first rib resection to be
performed in the same hospital stay. If a significant steno-
sis remains after PTA, we favor the placement of a self-
expanding stent. These are readily available, are available in
sizes that match the subclavian vein, and are flexible.
CONCLUSION
The findings of this study support existing data5,19,25
that early operative intervention is safe and effective after
catheter-directed thrombolysis for effort thrombosis of
the subclavian vein. PTA after first rib resection that is per-
formed after thoracic inlet decompression produces excel-
lent long-term patency and symptomatic relief. Patients
with short-segment venous strictures that persist after PTA
may be safely treated with subclavian venous stents and
can expect long-term patency.
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